Aurora Cannabis showcased a strong performance with record revenue and growth metrics, particularly in the international medical cannabis market. Despite some temporary challenges in Poland and a decline in consumer cannabis revenue, the company's strategic focus on high-margin international markets and improvements in financial metrics contributed to a largely positive outlook.

Company Guidance -

Q4 2025

During the Aurora Cannabis Inc. fiscal fourth quarter 2025 results conference call, the company provided notable guidance metrics, highlighting a record-setting fiscal year with net revenue rising by 27% to $343 million, primarily driven by a 39% increase in global medical cannabis revenue. Adjusted gross margin improved to 55%, while adjusted EBITDA reached nearly $50 million, and positive free cash flow was around $10 million. The company's balance sheet remains robust with $185 million in cash and no debt in the cannabis business. Aurora's focus on the medical cannabis segment, which constituted 75% of net revenue, led to international market growth, particularly in Australia and Europe, despite regulatory challenges in Poland. Moving into fiscal 2026, the company anticipates continued strong performance in global medical cannabis revenue, particularly in Europe and Australia, with expectations of slightly lower Q1 2026 global cannabis revenue due to temporary international market declines. However, margins are expected to remain strong, and free cash flow should stay positive.

Record-Breaking Revenue and Growth

Net revenue rose 27% to a record $343 million, with global medical cannabis revenue increasing 39%. Adjusted gross margin improved to 55% compared to 49% in the previous year.

Strong International Performance

International revenue comprised over half of total global medical cannabis, up from 41% in fiscal 2024. International medical cannabis revenue grew 114%.

Improved Financial Metrics

Record adjusted EBITDA of almost $50 million and record positive free cash flow of about $10 million. Consolidated adjusted gross margin at 62%, a 1200 basis points increase from the previous year.

Expansion in Global Markets

Aurora expanded its product portfolio in Australia and launched new products in Germany and the U.K. Maintained leadership positions in multiple countries including Canada, Australia, and Germany.

Aurora Cannabis (TSE:ACB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:ACB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2026 (Q1)	0.16 / -	0.08	―	―	―
Jun 18, 2025	2025 (Q4)	0.13 / -0.35	-0.4	12.50% (+0.05)
Feb 05, 2025	2025 (Q3)	<0.01 / 0.57	-0.5	214.00% (+1.07)
Nov 06, 2024	2025 (Q2)	-0.11 / -0.22	0	―
Aug 07, 2024	2025 (Q1)	-0.17 / 0.08	-0.8	110.00% (+0.88)
Jun 20, 2024	2024 (Q4)	-0.18 / -0.40	13.626	-102.94% (-14.03)
Feb 08, 2024	2024 (Q3)	-0.13 / -0.50	-2.5	80.00% (+2.00)
Nov 09, 2023	2024 (Q2)	- / 0.00	-2	―
Sep 26, 2023	2023 (Q4)	- / -	-0.17	―	―	―
Aug 10, 2023	2024 (Q1)	-0.52 / -0.80	-1.7	52.94% (+0.90)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:ACB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jun 18, 2025	C$8.02	C$6.40	-20.20%
Feb 05, 2025	C$5.28	C$7.65	+44.89%
Nov 06, 2024	C$8.46	C$7.11	-15.96%
Aug 07, 2024	C$8.11	C$8.59	+5.92%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.